DePuy prices flotation in the middle of estimated range
This article was originally published in Clinica
Orthopaedics company DePuy has priced its initial public offering on the New York Stock Exchange at $17.50 a share, in the middle of the price range assumed in the prospectus. Of the 14.8 million shares offered, representing 15% of DePuy, 7.8 million were issued by the company and 7.0 million by its parent Corange, which also owns German diagnostics company Boehringer Mannheim.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.